328 related articles for article (PubMed ID: 29149944)
1. Management of Sepsis-Induced Immunosuppression.
Venet F; Rimmelé T; Monneret G
Crit Care Clin; 2018 Jan; 34(1):97-106. PubMed ID: 29149944
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.
Meisel C; Schefold JC; Pschowski R; Baumann T; Hetzger K; Gregor J; Weber-Carstens S; Hasper D; Keh D; Zuckermann H; Reinke P; Volk HD
Am J Respir Crit Care Med; 2009 Oct; 180(7):640-8. PubMed ID: 19590022
[TBL] [Abstract][Full Text] [Related]
3. [Advances in sepsis induced immunosuppression and immunomodulation therapy].
He X; Bo L; Jiang C
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Dec; 30(12):1202-1205. PubMed ID: 30592959
[TBL] [Abstract][Full Text] [Related]
4. [Reversing ICU-acquired immunosuppression: an innovative biomarker-guided therapeutic strategy for decreasing sepsis mortality and nosocomial infection rate].
Monneret G; Lepape A; Venet F
Pathol Biol (Paris); 2011 Dec; 59(6):329-33. PubMed ID: 21981928
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients presenting sepsis-induced immunosuppression: The GRID randomized controlled trial.
Vacheron CH; Lepape A; Venet F; Monneret G; Gueyffier F; Boutitie F; Vallin H; Schwebel C; Maucort-Boulch D; Friggeri A;
J Crit Care; 2023 Dec; 78():154330. PubMed ID: 37267804
[TBL] [Abstract][Full Text] [Related]
6. Down-modulation of granulocyte macrophage-colony stimulating factor receptor on monocytes during human septic shock.
Pangault C; Le Tulzo Y; Tattevin P; Guilloux V; Bescher N; Drénou B
Crit Care Med; 2006 Apr; 34(4):1193-201. PubMed ID: 16484916
[TBL] [Abstract][Full Text] [Related]
7. [Immunomodulation for sepsis: a change of tack?].
Leentjens J; Kox M; Pickkers P
Ned Tijdschr Geneeskd; 2014; 158():A6859. PubMed ID: 24518844
[TBL] [Abstract][Full Text] [Related]
8. Human leucocyte antigen (HLA-DR) gene expression is reduced in sepsis and correlates with impaired TNFα response: A diagnostic tool for immunosuppression?
Winkler MS; Rissiek A; Priefler M; Schwedhelm E; Robbe L; Bauer A; Zahrte C; Zoellner C; Kluge S; Nierhaus A
PLoS One; 2017; 12(8):e0182427. PubMed ID: 28771573
[TBL] [Abstract][Full Text] [Related]
9. Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma.
Flohé S; Lendemans S; Selbach C; Waydhas C; Ackermann M; Schade FU; Kreuzfelder E
Crit Care Med; 2003 Oct; 31(10):2462-9. PubMed ID: 14530752
[TBL] [Abstract][Full Text] [Related]
10. Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock.
Schefold JC; Zeden JP; Pschowski R; Hammoud B; Fotopoulou C; Hasper D; Fusch G; Von Haehling S; Volk HD; Meisel C; Schütt C; Reinke P
Scand J Infect Dis; 2010 Mar; 42(3):164-71. PubMed ID: 19958238
[TBL] [Abstract][Full Text] [Related]
11. Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients.
Rosenbloom AJ; Linden PK; Dorrance A; Penkosky N; Cohen-Melamed MH; Pinsky MR
Chest; 2005 Jun; 127(6):2139-50. PubMed ID: 15947332
[TBL] [Abstract][Full Text] [Related]
12. Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy.
Monneret G; Venet F
Cytometry B Clin Cytom; 2016 Jul; 90(4):376-86. PubMed ID: 26130241
[TBL] [Abstract][Full Text] [Related]
13. The immune system's role in sepsis progression, resolution, and long-term outcome.
Delano MJ; Ward PA
Immunol Rev; 2016 Nov; 274(1):330-353. PubMed ID: 27782333
[TBL] [Abstract][Full Text] [Related]
14. Marked alterations of neutrophil functions during sepsis-induced immunosuppression.
Demaret J; Venet F; Friggeri A; Cazalis MA; Plassais J; Jallades L; Malcus C; Poitevin-Later F; Textoris J; Lepape A; Monneret G
J Leukoc Biol; 2015 Dec; 98(6):1081-90. PubMed ID: 26224052
[TBL] [Abstract][Full Text] [Related]
15. Advances in the understanding and treatment of sepsis-induced immunosuppression.
Venet F; Monneret G
Nat Rev Nephrol; 2018 Feb; 14(2):121-137. PubMed ID: 29225343
[TBL] [Abstract][Full Text] [Related]
16. Monitoring immunomodulation in patients with sepsis.
Kyriazopoulou E; Giamarellos-Bourboulis EJ
Expert Rev Mol Diagn; 2021 Jan; 21(1):17-29. PubMed ID: 33183116
[No Abstract] [Full Text] [Related]
17. Identification of biomarkers of response to IFNg during endotoxin tolerance: application to septic shock.
Allantaz-Frager F; Turrel-Davin F; Venet F; Monnin C; De Saint Jean A; Barbalat V; Cerrato E; Pachot A; Lepape A; Monneret G
PLoS One; 2013; 8(7):e68218. PubMed ID: 23874546
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.
Hotchkiss RS; Monneret G; Payen D
Lancet Infect Dis; 2013 Mar; 13(3):260-8. PubMed ID: 23427891
[TBL] [Abstract][Full Text] [Related]
19. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma.
Lendemans S; Kreuzfelder E; Waydhas C; Schade FU; Flohé S
Inflamm Res; 2007 Jan; 56(1):38-44. PubMed ID: 17334669
[TBL] [Abstract][Full Text] [Related]
20. [Is a different view on the pathophysiology of sepsis the key for novel therapeutic options?].
Schlegel N; Flemming S; Meir M; Germer CT
Chirurg; 2014 Aug; 85(8):714-9. PubMed ID: 25103839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
